{
  "id": 11388048,
  "title": "Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab",
  "url": "https://urgent.news/2026/10/02/daiichi-sankyo-astrazenca-summit-partner-to-evaluate-datroway-plus",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T06:59:31.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/daiichi-sankyo-astrazenca-summit-partner-evaluate-datroway-plus-ivonescimab"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Daiichi Sankyo (4568.TS) and AstraZenca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple solid tumors, including lung and brea",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo",
        "url": "https://urgent.news/2026/10/02/astrazeneca-daiichi-sankyo-collaborate-with-summit-therapeutics-to",
        "published": "2026-10-02T06:55:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}